Cargando…

Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma

A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hongbeom, Kang, Kyung Nam, Shin, Yong Sung, Byun, Yoonhyeong, Han, Youngmin, Kwon, Wooil, Kim, Chul Woo, Jang, Jin-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352313/
https://www.ncbi.nlm.nih.gov/pubmed/32492943
http://dx.doi.org/10.3390/cancers12061443
_version_ 1783557608640086016
author Kim, Hongbeom
Kang, Kyung Nam
Shin, Yong Sung
Byun, Yoonhyeong
Han, Youngmin
Kwon, Wooil
Kim, Chul Woo
Jang, Jin-Young
author_facet Kim, Hongbeom
Kang, Kyung Nam
Shin, Yong Sung
Byun, Yoonhyeong
Han, Youngmin
Kwon, Wooil
Kim, Chul Woo
Jang, Jin-Young
author_sort Kim, Hongbeom
collection PubMed
description A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic cancer. Samples were divided into training and validation sets. Five linear or non-linear classification methods were used to determine the optimal model. Differences were identified in 10 out of the 11 markers tested. We identified 2047 combinations, all of which were applied to 5 separate algorithms. The new biomarker combination consisted of 6 markers (ApoA1, CA125, CA19-9, CEA, ApoA2, and TTR). The area under the curve, specificity, and sensitivity were 0.992, 95%, and 96%, respectively, in the training set. Meanwhile, the measures were 0.993, 96%, and 93% in the validation set. This study demonstrated the utility of multiple biomarker combinations in the early detection of PDAC. A diagnostic panel of 6 biomarkers was developed and validated. These algorithms will assist in the early diagnosis of PDAC.
format Online
Article
Text
id pubmed-7352313
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73523132020-07-21 Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma Kim, Hongbeom Kang, Kyung Nam Shin, Yong Sung Byun, Yoonhyeong Han, Youngmin Kwon, Wooil Kim, Chul Woo Jang, Jin-Young Cancers (Basel) Article A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic cancer. Samples were divided into training and validation sets. Five linear or non-linear classification methods were used to determine the optimal model. Differences were identified in 10 out of the 11 markers tested. We identified 2047 combinations, all of which were applied to 5 separate algorithms. The new biomarker combination consisted of 6 markers (ApoA1, CA125, CA19-9, CEA, ApoA2, and TTR). The area under the curve, specificity, and sensitivity were 0.992, 95%, and 96%, respectively, in the training set. Meanwhile, the measures were 0.993, 96%, and 93% in the validation set. This study demonstrated the utility of multiple biomarker combinations in the early detection of PDAC. A diagnostic panel of 6 biomarkers was developed and validated. These algorithms will assist in the early diagnosis of PDAC. MDPI 2020-06-01 /pmc/articles/PMC7352313/ /pubmed/32492943 http://dx.doi.org/10.3390/cancers12061443 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Hongbeom
Kang, Kyung Nam
Shin, Yong Sung
Byun, Yoonhyeong
Han, Youngmin
Kwon, Wooil
Kim, Chul Woo
Jang, Jin-Young
Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
title Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
title_full Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
title_fullStr Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
title_short Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
title_sort biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352313/
https://www.ncbi.nlm.nih.gov/pubmed/32492943
http://dx.doi.org/10.3390/cancers12061443
work_keys_str_mv AT kimhongbeom biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma
AT kangkyungnam biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma
AT shinyongsung biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma
AT byunyoonhyeong biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma
AT hanyoungmin biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma
AT kwonwooil biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma
AT kimchulwoo biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma
AT jangjinyoung biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma